๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The use of antidepressant drugs in general practice

โœ Scribed by K. Matthews; J. M. Eagles; C. A. Matthews


Publisher
Springer
Year
1993
Tongue
English
Weight
654 KB
Volume
45
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


The use of newly marketed drugs in child
โœ Lynda V. Wilton; Gillian Pearce; Ronald D. Mann ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB ๐Ÿ‘ 2 views

This study determined the licensed and `o label' (outside the terms of the licence) use of newly marketed medicines in children (2ยฑ11 years) and adolescents (12ยฑ17 years), by general practitioners in England. In addition, the incidence rates during the ยฎrst month of therapy (ID 1 ) for three adverse

The long-term use of psychotropic drugs:
โœ R. Fiorio; C. Bellantuono; M. Leoncini; G. Montemezzi; R. Micciolo; P. Williams ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 893 KB

## Abstract Four general practitioners (GPs) of Verona, a town in northern Italy of about 300,000 inhabitants, recruited in 1986 a cohort of 75 adult patients to whom they prescribed benzodiazepines or antidepressants for the โ€œfirst timeโ€. The patients, new users of psychotropic drugs, were 51 wome

Antidepressants in clinical practice: li
โœ Sidney H Kennedy; Beata S Eisfeld; Jeffrey H Meyer; R Michael Bagby ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 315 KB

There is a recognized gap between knowledge derived from 'efficacy' data - based on usually brief randomized controlled trials and findings in natural practice 'effectiveness' studies. In considering the limitations of current antidepressants in clinical practice, we have selected three clinically i

The use of antidepressants in clinical p
โœ R. H. McAllister-Williams; D. S. Baldwin; P. M. Haddad; S. Bazire ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB

## Abstract ## Objective Agomelatine (Valdoxanยฎ) is licensed by the European Medicines Agency for the treatment of major depressive episodes in adults. The objective of this review was to consider how the drug should be used in clinical practice in particular starting, stopping and switching to an